Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.

What Was Tested

This randomized controlled trial looks at Glucagon.

Who Took Part

The abstract describes 206 patients taking part.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults and older adults, both men and women.

This randomized, double-blind, statin-stratified, placebo-controlled, 4-arm, parallel-group study was conducted in patients with T2DM who were receiving background metformin.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

Groups ran in parallel: each of the patients stayed in one arm throughout.

Glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG) and safety endpoints were assessed at baseline and post baseline.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Metformin, Pyrazoles, Receptors, Glucagon and beta-Alanine.

The authors tagged it with the keywords glucagon receptor and phase 2 studies.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 206 patients.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, all human trials.